BYSI

BeyondSpring Inc. (NASDAQ:BYSI) is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in New York, New York. The company went public in March 2017 and focuses on developing innovative cancer therapies, particularly targeting chemotherapy-induced side effects and various forms of lung cancer. BeyondSpring's primary asset is Plinabulin, a novel drug that has completed Phase III clinical trials and represents the company's main pathway to potential commercialization and revenue generation.